Literature DB >> 16189744

Measurement of anticholinergic effects of psychotropic drugs in humans.

J Penttilä1, H Scheinin, E Syvälahti.   

Abstract

Psychotropic drugs are often liable to unwanted anticholinergic effects that reduce tolerance and compliance. Especially, in certain patient groups, such as elderly patients, anticholinergic adverse effects may be hazardous. There are also occasions in therapy when antimuscarinic activity is desired, e. g. in the treatment of neuroleptic-induced extrapyramidal symptoms with biperiden and other potent anticholinergic drugs. In this review, we describe various techniques to evaluate the anticholinergic influences of psychotropic drugs in vivo and also provide examples of previous human studies where these methods have been applied. By combining subjective ratings of anticholinergic effects to in vitro measurements of antimuscarinic activity in blood, as well as the functional state of salivary glands, sweat glands, heart and eye, a researcher can obtain a detailed anticholinergic profile of the drug in question, or a clinician can estimate the anticholinergic burden of his/her psychiatric patient who often uses multiple medications.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16189744     DOI: 10.1055/s-2005-873152

Source DB:  PubMed          Journal:  Pharmacopsychiatry        ISSN: 0176-3679            Impact factor:   5.788


  5 in total

1.  Central Anticholinergic Adverse Effects and Their Measurement.

Authors:  Pasi Lampela; Teemu Paajanen; Sirpa Hartikainen; Risto Huupponen
Journal:  Drugs Aging       Date:  2015-12       Impact factor: 3.923

Review 2.  Analysis of rapid heart rate variability in the assessment of anticholinergic drug effects in humans.

Authors:  Jani Penttilä; Tom Kuusela; Harry Scheinin
Journal:  Eur J Clin Pharmacol       Date:  2005-08-30       Impact factor: 2.953

3.  Anticholinergic drug use, serum anticholinergic activity, and adverse drug events among older people: a population-based study.

Authors:  Pasi Lampela; Piia Lavikainen; J Arturo Garcia-Horsman; J Simon Bell; Risto Huupponen; Sirpa Hartikainen
Journal:  Drugs Aging       Date:  2013-05       Impact factor: 3.923

4.  On-the-road driving performance after use of the antihistamines mequitazine and l-mequitazine, alone and with alcohol.

Authors:  N N J J M van der Sluiszen; A Vermeeren; S Jongen; E L Theunissen; A C M van Oers; C J Van Leeuwen; A Maret; C Desforges; A Delarue; J G Ramaekers
Journal:  Psychopharmacology (Berl)       Date:  2016-08-04       Impact factor: 4.530

5.  A Report of Rabbit Syndrome Who Benefited from Sigma 1 Agonist Fluvoxamine.

Authors:  Yakup Albayrak; Murat Beyazyüz; Özlem Abbak; Ece Altındağ
Journal:  Clin Psychopharmacol Neurosci       Date:  2019-02-28       Impact factor: 2.582

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.